- Dec. 22, 2025 - An article in WIRED on approval of an oral version of Novo Nordisk’s Wegovy featured obesity market insights from Citeline analyst Tim Blackstock
- Dec. 15, 2025 - An article from PharmaVoice on the Biosecure Act cited a statistic from Citeline’s Clinical Trials Roundup
- Dec. 8, 2025 - In a video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed how sponsors and CROs are adapting to evolving ICH GCP guidelines to ensure patient protection and preserve data integrity while maintaining innovation
- Dec. 8, 2025 - Applied Clinical Trials’ Dec. 5 ACT Brief podcast featured insights from Heidi Chen, Associate Director of Research & Commercial Services at Citeline, on the continued surge in CNS and autoimmune trials based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
- Dec. 8, 2025 - Applied Clinical Trials’ Dec. 8 ACT Brief podcast featured insights from Heidi Chen, Associate Director of Research & Commercial Services at Citeline, on how sponsors and CROs are maintaining innovation as they adapt to evolving ICH GCP guidelines
- Dec. 4, 2025 - Applied Clinical Trials’ Dec. 4 ACT Brief podcast featured insights from Heidi Chen, Associate Director of Research & Commercial Services at Citeline, on the shift toward more targeted and strategy-driven clinical development based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
- Dec. 4, 2025 - In a video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed the shift toward more targeted and strategy-driven clinical development based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
- Dec. 4, 2025 - In a video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed growth in CNS and autoimmune trials based on recent findings from the 2025 edition of Citeline’s Annual Clinical Trials Roundup
- Nov. 12, 2025 - In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed the trends of sponsors assuming a larger role in site selection and CRO oversight and using robust data that includes real-world data to validate feasibility before launch
- Nov. 12, 2025 - In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed converting identified patients into enrolled participants through organizing data assets, activating non-research HCPs, and building avenues for referral with compliant recompense
- Nov. 12, 2025 - Applied Clinical Trials’ Nov. 12 ACT Brief podcast featured insights from Matt Holms, Vice President of Sales at Citeline, on the growing trend of sponsors assuming greater data-backed oversight of site selection and CRO management
- Nov. 10, 2025 - In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed the need to tailor patient recruitment strategies by indication and geography and to adopt data-driven matching with supported referrals over site expansion and generic advertising
- Nov. 7, 2025 - Applied Clinical Trials’ ACT Brief podcast featured insights from Matt Holms, Vice President of Sales at Citeline, on the bottlenecks that continue to stall recruitment and initiatives that can help break through the logjam
- Nov. 6, 2025 - In a PharmaVoice article, Heidi Chen, Associate Director of Research and Commercial Services at Citeline and co-author of its annual Clinical Trials Roundup, discussed the accelerating research boom in China as well as other trends outlined in the report
- Nov. 6, 2025 - In a video interview with Applied Clinical Trials, Matt Holms, Vice President of Sales at Citeline, discussed how technology and data-driven strategies can help overcome the persistent barriers slowing patient recruitment
- Oct. 31, 2025 - A PharmaVoice article on the launch of a pivotal trial for MediciNova’s disease-modifying ALS drug MN-166 cited a statistic from Citeline’s Clinical Trials Roundup
- Oct. 23, 2025 - In an Endpoints article on the potential of neurology assets in M&As, Citeline analyst Emma Wille commented on how the adoption of AI might speed identification of successful candidates (subscription required)
- Oct. 24, 2025 - In a Fierce Pharma article, senior analyst David Dahan weighs in on the comeback of GSK's Blenrep
- Oct. 1, 2025 - In a PharmaVoice article, senior analyst Natasha Boliter discusses the opportunities and roadblocks around at-home vaccines
- Sept. 25, 2025 - In a Daily Mail article, David Wallace, Executive Editor of Generics Bulletin, sheds light on anticipated generic versions of weight-loss drugs (subscription required)
- Aug. 22, 2025 - A PharmaVoice article about recent large pharma breakups with biotechs cites data from the Pharma R&D Review
- July 29, 2025 - In an article in Precision Medicine Online about AstraZeneca’s Tagrisso’s Q2 success, Citeline analyst Neha Anand shares insights into growing competition in the ADC therapy market (subscription required)
- July 29, 2025 - In Part 5 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses what Emrelis could mean for AbbVie's long-term positioning in solid tumor treatment markets
- July 24, 2025 - In Part 4 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses what AbbVie's Emrelis approval means for pharma and biotech ADC strategies
- July 23, 2025 - In Part 3 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses how Emrelis is expanding treatment options for solid tumors with C-MET overexpression
- July 22, 2025 - In Part 2 of an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses how approval of AbbVie’s antibody-drug conjugate (ADC) Emrelis signals the FDA's posture toward ADCs in oncology
- July 21, 2025 - In an interview with Pharmaceutical Executive magazine, Citeline analyst Neha Anand discusses AbbVie’s newly approved antibody-drug conjugate (ADC) Emrelis
- July 18, 2025 - The New York Times cited Citeline data in an article on the impact proposed cuts to medical research and health agencies could have on drug development (subscription required)
- July 1, 2025 - A Forbes feature article includes Citeline data and insights from Daniel Chancellor, VP of Thought Leadership at Citeline's parent company, Norstella
- June 27, 2025 - Marketplace quotes Mark Landsell and Citeline data in an article on innovative drug development in China
- June 16, 2025 - In a BioXconomy article, deals analyst Jenny Tan sounds off on the BioNTech acquisition of CureVac
- June 16, 2025 - A Reuters article on US drugmakers turning to Chinese companies as they face patent expirations includes data from Citeline's Pharma R&D Review
- June 15, 2025 - A MedCity News article recapping ASCO 2025 features commentary from Citeline analyst Anna Simmons on breast cancer treatments
- May 30, 2025 - In a PharmaVoice article on the FDA’s approval of AbbVie’s ADC Emrelis, Citeline analyst Neha Anand offers commentary on the ADC market and challenges
- May 29, 2025 - In a commentary piece in Molecular Therapy, "The landscape of cell and gene therapy today," ASGCT's David Barrett and Citeline's Daniel Digaudio focus on advances in CGT (subscription required)
- May 15, 2025 - MedCity News has included analyst Neha Anand's commentary on FDA approval of AbbVie's ADC for lung cancer
- May 13, 2025 - UK national publication The i Paper featured commentary from Tim Blackstock on the potential uses of GLP-1s beyond obesity and diabetes
- April 25, 2025 - On the Pharmaceutical Commerce podcast, VP of Clinical Solutions Claire Riches dives into the FDA’s plans to use RWD to streamline the drug approval process
- April 22, 2025 - An article in Therapeutic Innovation & Regulatory Science notes how Citeline’s Trialtrove database was used to conduct an analysis to estimate the IRA’s impact on the initiation of industry-sponsored Phase I-III trials in previously approved drugs
- March 31, 2025 - Jake Mathon's insights are shared in a PharmaVoice article on adeno-associated viruses (AAV)
- March 11, 2025 - In an executive interview with The Clinical Trial Vanguard, Claire Riches, Vice President - Clinical Solutions, shares Citeline’s strategic vision for bridging clinical trials and real-world healthcare
- March 6, 2025 - In an article he wrote for MedCity News, Luca Parisi, Director of Clinical Analytics and Data Science, sees a promising future for the use of AI in drug development
- March 5, 2025 - A BioXconomy article on the AbbVie/Gubra deal for obesity drugs features Tim Blackstock’s comments
- Feb. 27, 2025 - Men’s Health, one of the UK's largest consumer health magazines, features Tim Blackstock’s commentary on the race to develop an oral weight loss drug
- Feb. 26, 2025 - A PharmaVoice article on the development of therapeutic cancer vaccines features commentary from James Drew, Director of Content Strategy - Technology
- Feb. 20, 2025 - An academic paper by Citeline subject matter experts and our quarterly ASGCT report were cited in an article on News Medical
- Feb. 16, 2025 - Citeline's US vs. China R&D comparison data was cited in an article in The Economist (subscription required)
- Feb. 10, 2025 - In an article for PharmaLive, Healthcare Analyst Emma Wille provides an overview of the depression treatment landscape from novel psychedelic therapies to traditional medicines
- Jan. 6, 2025 - Sara LaFever, executive director, product services, offers her predictions in PharmaVoice for promising drug approvals in 2025
- Dec. 12, 2024 - Healthcare analyst Emma Wille is quoted in an HCPLive article on the mental health crisis
- Dec. 10, 2024 - Senior analyst David Dahan offers commentary on GSK's antibody-drug conjugate Blenrep in PharmaVoice
- Dec. 5, 2024 - An article in The Economist on the weight-loss drug pipeline includes data provided by Citeline (subscription required)
- Dec. 1, 2024 - Dr. Annie Siu and Saakshi Gupta share their insights on 2025 trends for the APAC region in BioSpectrum Asia
- Nov. 20, 2024 - An article in PharmaVoice around the viability of the Biosecure Act quotes Pink Sheet Editor in Chief Nielsen Hobbs
- Oct. 16, 2024 - In an article on AstraZeneca’s Farxiga blockbuster drug, PharmaVoice references Citeline’s “Billion Dollar Blueprint: The Journey to Blockbuster Status” report
- Oct. 5, 2024 - Citeline data are referenced in a Financial Times article on GLP-1 weight-loss drugs (subscription required)
- Sept. 27, 2024 - In MedCity News, Summer Colling concurs with the prevailing belief that KarXT will not be a first-line treatment for schizophrenia
- Sept. 27, 2024 - Senior analyst Summer Colling provides commentary on the schizophrenia treatment KarXT in C&EN
- Sept. 16, 2024 - Nielsen Hobbs shared his predictions on the future of the BIOSECURE Act with PharmaVoice
- Sept. 12, 2024 - Commentary from analyst Nielsen Hobbs on the BIOSECURE Act is featured in STAT's DC Diagnosis Newsletter
- Aug. 30, 2024 - Pharmacy Times included commentary from Pam Spicer, therapy area director, on the current state of Alzheimer’s drugs coming to market and their potential impact on physicians and patients
- Aug. 27, 2024 - Data from Trialtrove was included in a Financial Times (MUU: 36,500,000) article on the current landscape for oncology treatment (registration required)
- Aug. 23, 2024 - Therapy Area Director Pam Spicer is featured in a Pharmacy Times “Pharmacy Focus” podcast on the current pipeline of Alzheimer’s drugs
- Aug. 4, 2024 - Brian Yang’s commentary was included in an in-depth The Wire China article discussing Novo Nordisk’s Ozempic, the GLP-1 market in China, and the wider Chinese biopharma industry (subscription required)
- June 21, 2024 - A MedCity News article cites both principal analyst Amanda Micklus and Citeline data regarding precedents for the Sarepta gene therapy approval
- June 13, 2024 - Endpoints News cited Citeline figures on Lu-177 trials in an article warning of a shortage of lutetium (registration required)
- June 5, 2024 – In its ASCO coverage, PharmaLive and its Daily Advantage newsletter included commentary from several Citeline analysts
- June 3, 2024 - Claire Riches is interviewed regarding her role as a woman leader in pharma on The Pharma Recruiter podcast
- May 30, 2024 - Swiss national publication Swissinfo, part of the Swiss Broadcasting Corporation, included a graphic with Citeline data on AI dealmaking
- May 17, 2024 — Life Science Sweden ran a dedicated analysis of the Annual Pharma R&D Review and its insights, including an interview with Ian Lloyd
- May 8, 2024 — In an article in The Times, Dan Chancellor provides context for AstraZeneca's withdrawal of its COVID-19 vaccine. (subscription required)
- May 2, 2024 — In
an article on Q1 earnings, MM&M featured commentary on Moderna from analyst Flora Mackay
- Apr. 25, 2024 — Analyst Dana Gheorge is quoted in an Investor's Business Daily article on radiopharmaceuticals
- Apr. 24, 2024 — As part of our quarterly earnings analyses, MM+M featured Joseph Jacob’s commentary
around Roche’s Q1 earnings
- Mar. 30, 2024 — The Economist featured Citeline data on AI-related pharmaceutical expenditures in its
Technology Quarterly on healthcare and AI
- Mar. 7, 2024 — David Ridley offers his insights in an article in The Economist on nootropics
- Mar. 7, 2024 — New Scientist included a comment from Dan Chancellor on Novo Nordisk’s Phase I
trial readout for amycretin
- Mar. 6, 2024 — Analyst Summer Colling is extensively quoted in PharmaVoice (19.7K+ UVM) around
schizophrenia treatment innovation
- Feb. 26, 2024 — Analyst Khang Koang
is quoted in PharmaVoice in an article on the skyrocketing sales of diabetes and weight loss GLP-1
receptors
- Feb. 21, 2024 — A
PharmaVoice article on biotechs to watch in 2024 uses data and quotes from Biomedtracker's forecasting
report
- Feb. 15, 2024 — PharmaVoice quoted Therapy Area Director Pam Spicer in an article
on Biogen’s Q4 earnings
- Feb. 15, 2024 — City A.M. included Dan Chancellor’s commentary on GSK’s acquisition of Aiolos
Bio
- Feb. 13, 2024 — Khang Hoang, Citeline cardiovascular and metabolic and infectious diseases analyst, is quoted in
Drug Discovery & Development on additional indications for GLP-1s
- Feb. 13, 2024 — Investor’s Business Daily included comments from analyst Pamela Spicer on Biogen's
Q4 earnings, focusing on the slow launch of Leqembi
- Feb. 8, 2024 — UK business national This Is Money included healthcare analyst Summer Colling's
commentary on AstraZeneca earnings in its live business blog
- Jan. 22, 2024 — In
a PharmaVoice article on a universal COVID vaccine, senior analyst Natasha Boliter shares her insights on
the logistical advantage of a combination COVID, RSV, and flu vaccine
- Jan. 22, 2024 — PharmaVoice included commentary from Jake Mathon and Sheila Omondi around challenge
trials, as well as supporting data from Citeline
- Jan. 5, 2024 — A
PharmaVoice article on the state of infectious disease featured comments from senior analysts Natasha
Boliter and Charlotte Holmes
- Dec. 20, 2023 — In an article on blockbuster drugs, PharmaVoice included commentary from Dan Chancellor
and Sara LeFever, as well as Citeline and Evaluate data
- Dec. 12, 2023 — Proactive Investors featured Dan Chancellor’s analysis in an article discussing the
significance of the AstraZeneca/Icosavax acquisition
- Dec. 12, 2023 — This is Money included Dan Chancellor’s comments on AstraZeneca’s agreement
to purchase vaccine specialist Icosavax
- Dec. 8, 2023 — PharmaVoice featured Citeline and Evaluate data with commentary from The Dedham
Group’s Jen Klarer around FDA approval of the CRISPR-based sickle-cell anemia treatment Casgevy
- Dec. 6, 2023 — Endpoints News quoted analyst Xin Zhao on the UK government’s new voluntary program
for branded medicines pricing, access and growth (VPAG)
- Dec. 4, 2023 — Chemical &
Engineering News included Fenwick Eckhardt’s comments in a comprehensive roundup of the largest
events and
breakthroughs in the pharma space in 2023
- Dec. 4, 2023 — PharmaVoice featured Dan Chancellor's commentary on Pharma M&A
- Nov. 28, 2023 — Patricia
Giglio, Director of Deals Intelligence, is quoted in a PharmaVoice article on the top 5 IPOs of 2023 in
biopharma
- Nov. 27, 2023 — C&EN featured comments from Malcolm Spicer around the effectiveness of OTC cold
medications
- Nov. 8, 2023 — Senior analyst Natasha Boliter is the sole expert quoted in a PharmaVoice article on
AstraZeneca’s self-administered flu vaccine
- Nov. 7, 2023 — New Scientist featured Dana Gheorge’s comments on approval of the drug anastrozole
for breast cancer prevention
- Nov. 2, 2023 — Investor’s Business Daily featured senior analyst Jeff Stevens’ commentary on
Moderna Q3 earnings
- Nov. 2, 2023 — PharmaVoice included commentary from Dan Chancellor, Director of Thought Leadership,
regarding the pharmaceutical landscape in 2023
- Nov. 1, 2023 — International Clinical Trials
interviewed Luca Parisi on AI in clinical trial settings and how it can be used in line with human involvement to
positively change all stages of drug development
- Oct. 31, 2023 — Investor’s Business Daily included Zhyar Said’s commentary on Pfizer’s
Q3 earnings
- Oct. 24, 2023 — Analyst Mille Gray is quoted exclusively in a PharmaNewsIntelligence article on the
breast cancer therapeutics market
- Oct. 23, 2023 — Luca Parisi, Citeline Director of Clinical Analytics, was interviewed on the FUTRtech
podcast; he discusses how AI and data are revolutionizing drug development
- Oct. 17, 2023 — Haley Quinn, Go To Market Director of Patient Engagement and Recruitment, advocated for better
rare disease trial design in ACRP's Clinical Researcher
- Oct. 17, 2023 — Reuters included Ellie Davenport insights on Keytruda’s FDA nod for expanded use in
lung cancer
- Sept. 29, 2023 — Dan Chancellor shared his insights in Investor’s Business
Daily
on how FDA approval of exa-cel would change future uptake for allogenic gene therapies
- Sept. 22, 2023 — Dan Chancellor was quoted in MM+M on the expanded indication of
Jardiance for chronic kidney disease
- Sept. 14, 2023 — In an article on the adoption of weight-loss drugs, Pharma
Manufacturing cited statistics from Citeline’s Pharmaprojects database
- Sept. 11, 2023 — MM+M shared Dan Chancellor’s insight on the relationship between the Inflation
Reduction Act (IRA) and the recent pullback of DTC marketing budgets
- Sept. 9, 2023 — The Guardian included Jeffrey Stevens’ comments and Evaluate forecasts on the
obesity drug Wegovy
- Sept. 5, 2023 — PharmaVoice included commentary from Ellie Davenport on the Roche trial data
leak
- Sept. 1, 2023 — Life Science Leader published an article by Dan Chancellor on addressing the
uncertainties of the IRA in biopharma
- Aug. 10, 2023 — CNBC included commentary from Zhyar Said on Wegovy and Ozempic
- Aug. 10, 2023 — Emma Wille is quoted in article on the potential impact of the FDA’s rejection of zuranolone
for MDD in Drug Discovery and Development
- Aug. 10, 2023 — PharmaVoice featured Dan Chancellor’s commentary on biotech IPOs
- Aug. 3, 2023 — Quartz quoted Nielsen Hobbs around the impact of the mifepristone ruling on the broader
pharmaceutical industry
- July 26, 2023 — Finance and business publication Shares included Zhyar Said’s comment around
GSK’s Q2 earnings in in its expert view section
- July 20, 2023 — Investor’s Business Daily featured commentary on J&J earnings from Zhyar
Said
- July 20, 2023 — Coverage in CE&N around Donanemab Phase III results
- July 17, 2023 — The Financial Times used Datamonitor Healthcare forecasts in its article covering
the release of Eli Lilly’s donanemab data
- July 6, 2023 — The Washington Post quoted Pam Spicer on the rollout of Leqembi
- July 1, 2023 — The
Motley Fool mentioned a Citeline report to make an assessment on Pfizer’s health as a company
- June 25, 2023 — Coverage in C&EN (458.9K+ UVM) for Anna Osborne around cancer vaccines
- June 20, 2023 — PharmaVoice quoted Bridget Silverman on the future of accelerated approvals at the
FDA
- June 16, 2023 — C&EN featured commentary from Peter Chang on the Novartis acquisition of Chinook
- June 9, 2023 — Coverage in Pharma Manufacturing in its three-part series around antibody-drug
conjugates, with our data cited throughout parts one and three
- May 8, 2023 — PharmaVoice included Sara LaFever’s commentary on three key FDA approval trends
this year
- May 8, 2023 — Reuters featured Citeline data in article on weight-loss drugs
- May 4, 2023 — C&EN included Andrew McConaghie’s commentary around the FDA’s approval of
GSK’s RSV vaccine
- May 3, 2023 — Citeline’s data on AI applications for biopharma companies was cited in
Pharmaphorum
- May 2, 2023 — Zhyar
Said’s commentary was featured in Investor’s Business Daily around Pfizer’s Q1 earnings
results
- April 13, 2023 — Citeline was mentioned in The Medicine Maker alongside data from Pharmaprojects around
drug R&D
- April 7, 2023 — The Guardian featured Anna Osborne’s commentary on mRNA cancer vaccines
- April 6, 2023 — C&EN included Jeffrey Stevens’ commentary around how GSK is beefing up its
infectious disease portfolio with an antifungal from firm Scynexi
- March 28, 2023 — C&EN featured Pam Spicer’s commentary around Biogen’s ALS drug,
tofersen
- March 7, 2023 — Mike Gallup and Ashley Schwalje shared a byline in Applied Clinical Trials, highlighting
the role data technology will play in transforming clinical trial design
- March 2, 2023 — The Economist featured Dan Chancellor’s commentary on the current landscape for
obesity drugs
- Feb. 23, 2023 — Investor's Business Daily included Zhyar Said’s commentary around Moderna’s
Q4 earnings announcement
- Feb. 10, 2023 — C&EN featured Dan Chancellor’s commentary around Structure Therapeutics’
IPO
- Feb. 3, 2023 — C&EN featured commentary from Pam Spicer on the biosimilars landscape
- Feb. 1, 2023 — City A.M. shared commentary from Zhyar Said on GSK’s earnings
- Jan. 30, 2023 — PharmaVoice included insights from Dan Chancellor on how the weight loss pharma space
will be realizing its potential with new high-dose GLP-1 agonists
- Jan. 24, 2023 — Investor's Business Daily included Zhyar Said’s commentary following
J&J’s Q4 earnings announcement
- Jan. 17, 2023 — PharmaVoice featured extensive insights from Amanda Micklus on the pharma M&A
- Jan. 12, 2023 — C&EN included commentary from Sara LaFever on the JP Morgan Healthcare
Learn More About Citeline
